APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
The TH1/TH2 Response Imbalance Zika Virus Pathogenesis: An Immunological Paradox.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Menezes Carla, Martins Lívia, Ferro Gustavo, Arnaud Bernard, Quaresma Juarez, Vasconcelos Pedro, Sousa Jorge
Аннотация
Since its identification in 1947 and its global emergence in the Americas decades later, the Zika virus (ZIKV) has proven to be a multifaceted challenge to public health. Among the many aspects that remain poorly understood, the complex immunological paradox between Th1 and Th2 responses stands out, playing a central role in the immunopathogenesis of the infection. This narrative review critically explores how scientific literature has addressed this duality, highlighting that an exacerbated Th1 response-although effective in viral containment-is frequently associated with severe outcomes, such as heightened inflammation and autoimmune manifestations, including Guillain-Barré syndrome. Conversely, a predominant Th2 profile, generally linked to milder clinical presentations, may favor viral persistence and, paradoxically, contribute to late-onset neurological complications, such as encephalitis. Additionally, we discuss the central role of interactions between CD4+ and CD8+ T cells, monocytes, NK cells, and B cells, which, although essential for immune control of the infection, may, when dysregulated, exacerbate pathogenesis. By unraveling the mechanisms behind this delicate balance between antiviral defense and immune-mediated damage, we aim to shed light on new therapeutic perspectives. Understanding the nature and consequences of this Th1/Th2 paradox is crucial for guiding the development of immunomodulatory strategies that foster an effective response against ZIKV, while minimizing the risk of neurological injury.